Mission Wealth Management LP Has $3.53 Million Position in Agilent Technologies, Inc. (NYSE:A)

Mission Wealth Management LP boosted its holdings in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 52.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,357 shares of the medical research company's stock after buying an additional 8,739 shares during the period. Mission Wealth Management LP's holdings in Agilent Technologies were worth $3,525,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. OFI Invest Asset Management bought a new position in shares of Agilent Technologies during the third quarter valued at $25,000. MV Capital Management Inc. raised its holdings in shares of Agilent Technologies by 120.7% in the fourth quarter. MV Capital Management Inc. now owns 192 shares of the medical research company's stock valued at $27,000 after buying an additional 105 shares during the last quarter. Baystate Wealth Management LLC raised its holdings in shares of Agilent Technologies by 107.3% in the fourth quarter. Baystate Wealth Management LLC now owns 257 shares of the medical research company's stock valued at $36,000 after buying an additional 133 shares during the last quarter. Column Capital Advisors LLC raised its holdings in shares of Agilent Technologies by 1,111.1% in the third quarter. Column Capital Advisors LLC now owns 327 shares of the medical research company's stock valued at $37,000 after buying an additional 300 shares during the last quarter. Finally, Rosenberg Matthew Hamilton raised its holdings in shares of Agilent Technologies by 51.1% in the fourth quarter. Rosenberg Matthew Hamilton now owns 284 shares of the medical research company's stock valued at $39,000 after buying an additional 96 shares during the last quarter.

Analyst Ratings Changes

Several analysts have weighed in on the company. Evercore ISI boosted their price objective on Agilent Technologies from $132.00 to $145.00 and gave the stock an "in-line" rating in a report on Thursday, April 4th. UBS Group boosted their price objective on Agilent Technologies from $130.00 to $155.00 and gave the stock a "neutral" rating in a report on Wednesday, February 28th. Stifel Nicolaus raised Agilent Technologies from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $145.00 to $163.00 in a report on Friday, April 5th. Oppenheimer boosted their price objective on Agilent Technologies from $67.00 to $90.00 and gave the stock an "outperform" rating in a report on Tuesday, March 26th. Finally, Barclays boosted their target price on Agilent Technologies from $125.00 to $135.00 and gave the stock an "underweight" rating in a research report on Wednesday, April 10th. One analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, Agilent Technologies currently has an average rating of "Moderate Buy" and an average target price of $141.29.

Agilent Technologies Stock Performance

NYSE A traded down $2.55 on Tuesday, reaching $137.04. The stock had a trading volume of 1,087,283 shares, compared to its average volume of 1,547,172. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.68 and a quick ratio of 2.04. The firm has a fifty day moving average of $141.69 and a two-hundred day moving average of $131.02. Agilent Technologies, Inc. has a 1-year low of $96.80 and a 1-year high of $151.58. The company has a market cap of $40.16 billion, a P/E ratio of 33.24, a price-to-earnings-growth ratio of 4.17 and a beta of 1.11.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings data on Tuesday, February 27th. The medical research company reported $1.29 EPS for the quarter, beating analysts' consensus estimates of $1.22 by $0.07. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. The firm had revenue of $1.66 billion for the quarter, compared to analyst estimates of $1.59 billion. During the same period in the prior year, the firm posted $1.37 EPS. The company's revenue for the quarter was down 5.5% on a year-over-year basis. On average, equities research analysts anticipate that Agilent Technologies, Inc. will post 5.5 EPS for the current year.

Agilent Technologies Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 24th. Stockholders of record on Tuesday, April 2nd were issued a dividend of $0.236 per share. This represents a $0.94 annualized dividend and a dividend yield of 0.69%. The ex-dividend date was Monday, April 1st. Agilent Technologies's dividend payout ratio (DPR) is currently 22.38%.

Insider Transactions at Agilent Technologies

In related news, SVP Philip Binns sold 2,827 shares of the firm's stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $147.54, for a total value of $417,095.58. Following the sale, the senior vice president now directly owns 9,997 shares of the company's stock, valued at $1,474,957.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Heidi Fields sold 1,658 shares of the firm's stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total transaction of $239,315.72. Following the completion of the transaction, the director now directly owns 54,976 shares in the company, valued at $7,935,235.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Philip Binns sold 2,827 shares of the firm's stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $147.54, for a total value of $417,095.58. Following the transaction, the senior vice president now owns 9,997 shares of the company's stock, valued at $1,474,957.38. The disclosure for this sale can be found here. In the last three months, insiders have sold 61,610 shares of company stock valued at $9,220,333.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.